Vortioxetine (Lu AA21004) HBr

Catalog No.S8021

Vortioxetine (Lu AA21004) is a multimodal serotonergic agent, inhibits 5-HT1A, 5-HT1B, 5-HT3A, 5-HT7 receptor and SERT with IC50 of 15 nM, 33 nM, 3.7 nM, 19 nM and 1.6 nM, respectively.

Price Stock Quantity  
USD 410 In stock
USD 147 In stock
USD 997 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Vortioxetine (Lu AA21004) HBr Chemical Structure

Vortioxetine (Lu AA21004) HBr Chemical Structure
Molecular Weight: 379.36

Validation & Quality Control

Quality Control & MSDS

Product Information

  • Compare 5-HT Receptor Modulators
    Compare 5-HT Receptor Products
  • Research Area
  • Inhibition Profile

Product Description

Biological Activity

Description Vortioxetine (Lu AA21004) is a multimodal serotonergic agent, inhibits 5-HT1A, 5-HT1B, 5-HT3A, 5-HT7 receptor and SERT with IC50 of 15 nM, 33 nM, 3.7 nM, 19 nM and 1.6 nM, respectively.
Targets SERT [1] 5-HT3A [1] 5-HT1A [1] 5-HT7 [1] 5-HT1B [1]
IC50 1.6 nM(Ki) 3.7 nM(Ki) 15 nM(Ki) 19 nM(Ki) 33 nM(Ki)
In vitro Lu-AA21004 inhibits recombinant human CYP1A2, CYP2C9, CYP2D6 and CYP3A4 with IC50 of 40 μM, 39 μM, 9.8 μM and 10 μM, respectively. [1] Lu AA21004 is a partial h5-HT1B receptor agonist with EC50 of 460 nM and intrinsic activity of 22% using a whole-cell cAMP-based assay. Lu AA21004 binds to the r5-HT7 receptor with a Ki value of 200 nM and is a functional antagonist at the r5-HT7 receptor with an IC50 of 2 μM in an in vitro whole-cell cAMP assay. [2]
In vivo For Lu-AA21004 the hepatic clearances and oral bioavailabilities in rats are found to be 7.1 (L/h)/kg and 16%. Lu-AA21004 (2.5 mg/kg, 5 mg/kg, or 10 mg/kg sc) increases the extracellular levels of 5-HT in the ventral hippocampus in conscious rats. Lu-AA21004 (5 mg/kg, or 10 mg/kg sc) also results in significantly higher basal levels of 5-HT in the medial prefrontal cortex (mPFC) after 3 days of treatment. Lu-AA21004 occupies SERT by 43% and 57% after 3 days of treatment with 5 mg/kg or 10 mg/kg in the rat medial prefrontal cortex. [1] Lu AA21004 dose-dependent occupies 5-HT1B receptor and the SERT with ED50 of 3.2 mg/kg and 0.4 mg/kg in rats one hour after subcutaneous administration. Lu AA21004 affects the Bezold-Jarisch reflex in the rat dose dependently, inhibiting transient bradycardia with ED50 of 0.11 mg/kg. Lu AA21004 (2.5-10.0 mg/kg s.c.) increases extracellular levels of 5-HT, DA, and NA in the medial prefrontal cortex and in the ventral hippocampus in rats. Lu AA21004 (5 mg/kg s.c.) increases in the extracellular levels of 5-HT (200%) in the ventral hippocampus of rats with 41% occupancy at the SERT. Lu AA21004 (7.8 mg/kg s.c.) significantly decreases the immobility time in the FSL rats but not in the FRL rats. Lu AA21004 (8.0 mg/kg p.o.) produces an increase in social interaction as well as a small, but significant, increase in locomotor activity in rats. Lu AA21004 (7.9 mg/kg s.c.) shows a dose-dependent anxiolytic-like effect in the conditioned fear assay in rats. [2] Vortioxetine (10 mg/kg) significantly increases freezing 60 min before acquisition in male Sprague-Dawley rats, suggesting enhanced contextual memory formation during acquisition and/or consolidation. Vortioxetine (5 mg/kg) also causes increased freezing rates during retention, an effect that reached statistical significance by post hoc tests. Vortioxetine (2.5 mg/kg or 5 mg/kg) prior to acquisition shows average exploration times of 29s and 33s for the novel object, respectively. Vortioxetine (10 mg/kg) significantly reduces nociception in rats, assessed as increased paw withdrawal latency. Vortioxetine at 5 and 10 mg/kg increases the levels of ACh to 224% and 204% of baseline 20 min after injection. [3]
Features A multimodal antidepressant.

Protocol(Only for Reference)

Kinase Assay: [1]

h5-HT3A Binding Affinity Assay [3H]Granisetron (1 nM) binding to h5-HT3A receptors is evaluated in membranes from a HEK-293 cell line stably expressing the hHT3A receptor. Nonspecific binding is measured in the presence of 10 μM bemesetron. After incubation, the membrane preparations are rapidly filtered under a vacuum using glass-fiber filters. Lu-AA21004 are tested at least three times over a 6 log concentration range. IC50 values are determined by nonlinear regression analysis using Hill equation curve fitting, and Ki values are calculated based on the Cheng−Prusoff equation.

Animal Study: [1]

Animal Models Rats
Formulation 10% hydroxypropyl-β-cyclodextrin
Dosages 10 mg/kg
Administration Subcutaneous

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)


[1] Bang-Andersen B, et al. J Med Chem, 2011, 54(9), 3206-3221.

[2] M?rk A, et al. J Pharmacol Exp Ther, 2012, 340(3), 666-675.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2015-11-14)

NCT Number Recruitment Conditions Sponsor
Start Date Phases
NCT02528409 Not yet recruiting Binge Eating Disorder University of Chicago|Takeda October 2015 Phase 2
NCT02559947 Not yet recruiting Major Depressive Disorder Psychiatric Medicine Associates, L.L.C.|Takeda Pharmaceut  ...more Psychiatric Medicine Associates, L.L.C.|Takeda Pharmaceuticals North America, Inc.|ElMindA Ltd October 2015 Phase 4
NCT02357797 Not yet recruiting Schizophrenia|Negative Symptoms North Shore Long Island Jewish Health System|Takeda September 2015 Phase 4
NCT02234362 Recruiting Depression|Menopause|Vasomotor Disturbance|Hot Flashes|Sleep Massachusetts General Hospital|Takeda Pharmaceuticals Nor  ...more Massachusetts General Hospital|Takeda Pharmaceuticals North America, Inc. July 2015 Phase 4
NCT02454426 Not yet recruiting Major Depressive Disorder|Coronary Artery Disease Thomas Jefferson University|Takeda June 2015 Phase 0

view more

Chemical Information

Download Vortioxetine (Lu AA21004) HBr SDF
Molecular Weight (MW) 379.36


CAS No. 960203-27-4
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 76 mg/mL (200.33 mM)
Ethanol 17 mg/mL (44.81 mM)
Water <1 mg/mL (<1 mM)
In vivo 15% Captisol, pH 9 10 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name Piperazine, 1-[2-[(2,4-dimethylphenyl)thio]phenyl]-, hydrobromide (1:1)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related 5-HT Receptor Products

  • AZD3839

    AZD3839 is a potent and selective BACE1 inhibitor with Ki of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.

  • Xanthohumol

    Xanthohumol, a prenylated chalcone from hop, inhibits COX-1 and COX-2 activity and shows chemopreventive effects. Phase 1.

  • A-438079 HCl

    A-438079 HCl is a potent, and selective P2X7 receptor antagonist with pIC50 of 6.9.

  • Fluoxetine HCl

    Fluoxetine is a selective serotonin-reuptake inhibitor (SSRI) at the neuronal membrane, used in the treatment of depression.

  • WAY-100635 Maleate

    WAY-100635 Maleate is a potent and selective 5-HT receptor antagonist with IC50 of 0.95 nM.

    Features:Characterised as the first 5-HT1A antagonist radioligand.

  • Ketanserin

    Ketanserin is a specific 5-HT2A serotonin receptor antagonist with Ki of 2.5 nM for rat and human 5-HT2A, used as an antihypertensive drug.

  • Prucalopride Succinate

    Prucalopride is a selective, high affinity 5-HT4 receptor agonist, inhibiting human 5-HT(4a) and 5-HT(4b) receptor with Ki value of 2.5 nM and 8 nM, respectively.

  • Asenapine maleate

    Asenapine maleate is a high-affinity antagonist of serotonin, norepinephrine, dopamine and histamine receptors, used for the treatment of schizophrenia and acute mania associated with bipolar disorder.

  • Iloperidone

    Iloperidone is a dopamine (D2)/serotonin (5-HT2) receptor antagonist, used for the treatment of schizophrenia.

  • Duloxetine HCl

    Duloxetine HCl is a serotonin-norepinephrine reuptake inhibitor with Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD).

Recently Viewed Items

Tags: buy Vortioxetine (Lu AA21004) HBr | Vortioxetine (Lu AA21004) HBr supplier | purchase Vortioxetine (Lu AA21004) HBr | Vortioxetine (Lu AA21004) HBr cost | Vortioxetine (Lu AA21004) HBr manufacturer | order Vortioxetine (Lu AA21004) HBr | Vortioxetine (Lu AA21004) HBr distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us